HK1118807A1 - Potentiator for radiation therapy comprising pyridine derivative as active ingredient - Google Patents

Potentiator for radiation therapy comprising pyridine derivative as active ingredient

Info

Publication number
HK1118807A1
HK1118807A1 HK08109853.9A HK08109853A HK1118807A1 HK 1118807 A1 HK1118807 A1 HK 1118807A1 HK 08109853 A HK08109853 A HK 08109853A HK 1118807 A1 HK1118807 A1 HK 1118807A1
Authority
HK
Hong Kong
Prior art keywords
potentiator
active ingredient
radiation therapy
pyridine derivative
pyridine
Prior art date
Application number
HK08109853.9A
Other languages
English (en)
Inventor
Masakazu Fukushima
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of HK1118807A1 publication Critical patent/HK1118807A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK08109853.9A 2005-04-01 2008-09-04 Potentiator for radiation therapy comprising pyridine derivative as active ingredient HK1118807A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005105938 2005-04-01
JP2005219119 2005-07-28
PCT/JP2006/306961 WO2006106984A1 (ja) 2005-04-01 2006-03-31 ピリジン誘導体を有効成分とする放射線治療増強剤

Publications (1)

Publication Number Publication Date
HK1118807A1 true HK1118807A1 (en) 2009-02-20

Family

ID=37073534

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08109853.9A HK1118807A1 (en) 2005-04-01 2008-09-04 Potentiator for radiation therapy comprising pyridine derivative as active ingredient

Country Status (12)

Country Link
US (2) US20090137640A1 (zh)
EP (1) EP1864974B1 (zh)
JP (1) JP5103170B2 (zh)
KR (1) KR101135789B1 (zh)
AU (1) AU2006231809B2 (zh)
BR (1) BRPI0608327A2 (zh)
CA (1) CA2603810C (zh)
HK (1) HK1118807A1 (zh)
NZ (1) NZ562048A (zh)
RU (1) RU2415670C2 (zh)
TW (1) TWI371447B (zh)
WO (1) WO2006106984A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1864974B1 (en) * 2005-04-01 2013-10-09 Taiho Pharmaceutical Company Limited Potentiator for radiation therapy comprising pyridine derivative as active ingredient
KR20120015318A (ko) * 2009-05-12 2012-02-21 다이호야쿠힌고교 가부시키가이샤 테가푸르?기메라실?오테라실칼륨 배합제 및 옥살리플라틴을 함유하는 항종양제
CA2895526C (en) 2012-12-20 2021-08-24 Qing-bin LU Radiosensitizer compounds for use in combination with radiation
BR102013022567B1 (pt) * 2013-09-03 2021-09-21 Uniao Brasileira De Educacão E Assistência Uso de 6-hidroxi-2-piridonas e seus derivados na preparação de uma composição farmacêutica que atue pela inibição da enzima uridina fosforilase humana
CA3182871A1 (en) * 2020-06-15 2021-12-23 Kortuc Inc. Sensitizer for cancer treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6122016A (ja) * 1984-07-10 1986-01-30 Adeka Argus Chem Co Ltd 放射線増感剤
JPS61109719A (ja) * 1984-10-31 1986-05-28 Otsuka Pharmaceut Co Ltd 抗腫瘍活性増強剤
EP0180188B1 (en) * 1984-10-30 1992-04-15 Otsuka Pharmaceutical Co., Ltd. A composition for increasing the anti-cancer activity of an anti-cancer compound
JP2531952B2 (ja) * 1987-04-06 1996-09-04 大塚製薬株式会社 フオスホリラ−ゼ阻害剤
ATE455187T1 (de) * 2001-07-05 2010-01-15 Taiho Pharmaceutical Co Ltd Dna-arrays zur messung der empfindlichkeit gegenüber einem antikrebsmittel
RU2334517C2 (ru) * 2003-03-14 2008-09-27 Тайхо Фармасьютикал Ко., Лтд. Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство
EP1864974B1 (en) * 2005-04-01 2013-10-09 Taiho Pharmaceutical Company Limited Potentiator for radiation therapy comprising pyridine derivative as active ingredient
AU2006231808B2 (en) * 2005-04-01 2010-06-24 Taiho Pharmaceutical Co., Ltd. Radiotherapy enhancer

Also Published As

Publication number Publication date
EP1864974A1 (en) 2007-12-12
AU2006231809B2 (en) 2011-08-25
CA2603810C (en) 2012-06-26
BRPI0608327A2 (pt) 2009-12-29
TWI371447B (en) 2012-09-01
EP1864974A4 (en) 2009-09-02
WO2006106984A1 (ja) 2006-10-12
JP5103170B2 (ja) 2012-12-19
CA2603810A1 (en) 2006-10-12
US8569324B2 (en) 2013-10-29
EP1864974B1 (en) 2013-10-09
US20090137640A1 (en) 2009-05-28
KR20080002900A (ko) 2008-01-04
AU2006231809A1 (en) 2006-10-12
RU2007140384A (ru) 2009-05-10
KR101135789B1 (ko) 2012-04-16
TW200714588A (en) 2007-04-16
RU2415670C2 (ru) 2011-04-10
JPWO2006106984A1 (ja) 2008-09-25
NZ562048A (en) 2011-12-22
US20110091016A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
EP2093237A4 (en) ANTICANCER AGENT COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT
ZA200609765B (en) Therapeutic compounds: pyridine as scaffoid
EP1981547A4 (en) STABLE THERAPEUTIC FORMULATIONS
IL191907A0 (en) Azepinoindole derivatives as pharmaceutical agents
ZA200709999B (en) Fungicidal active ingredient combination
GB0518390D0 (en) Therapeutic compounds
GB0518237D0 (en) Therapeutic compounds
GB0509326D0 (en) Therapeutic compounds
GB0509573D0 (en) Therapeutic compounds
GB0518361D0 (en) Therapeutic compounds
GB0509405D0 (en) Therapeutic compounds
IL186359A0 (en) Synergistic fungicidal active substance combinations
ZA200804427B (en) Nanoparticulate active ingredient formulations
GB0513747D0 (en) Therapeutic compounds
ZA200709788B (en) Cannabinold active pharmaceutical ingredient for Improved dosage forms
IL201418A0 (en) Therapeutic agent for glaucoma containing adenosine derivative as active ingredient
ZA200804757B (en) Fungicidal active ingredient combination
EP2164328B8 (en) Therapeutic pyrazoloquinoline urea derivatives
HK1118807A1 (en) Potentiator for radiation therapy comprising pyridine derivative as active ingredient
GB0522130D0 (en) Therapeutic compounds
EP2152292A4 (en) ANGIOGENESIS HEMMER WITH METEORIN AS AN ACTIVE SUBSTANCE
GB0518235D0 (en) Therapeutic compounds
EP1928827A4 (en) PYRROLE DERIVATIVES AS THERAPEUTIC AGENTS
EP1967208A4 (en) THERAPEUTIC AGENT FOR SKIN OR AGENT PROMOTING REGENERATION OF SKIN CONTAINING GHRELINE, AND DERIVATIVES THEREOF OR SUBSTANCE CAPABLE OF ACTING AS ACTIVE INGREDIENT ON GHS-R1a
ZA200708367B (en) Potentiator for radiation therapy comprising pyridine derivative as active ingredient